Outlook Therapeutics (OTLK) Interest & Investment Income (2023 - 2024)
Outlook Therapeutics (OTLK) reported Interest & Investment Income of $239951.0 for Q3 2024, down 21.59% year-over-year from $306021.0 in Q4 2023, and down 40.69% quarter-over-quarter from $404593.0 in Q2 2024.
Outlook Therapeutics (OTLK) Interest & Investment Income (2023 - 2024) Analysis & Trends
Outlook Therapeutics (OTLK) has 2 years of Interest & Investment Income data on file, last reported at $239951.0 in Q3 2024.
- Interest & Investment Income for Q3 2024 came in at $239951.0, down 21.59% year-over-year; the trailing twelve-month figure through Sep 2024 was $1.3 million (changed N/A YoY), and the FY2025 annual result was $89738.0, down 90.1% from the prior year.
- Interest & Investment Income retreated to $239951.0 in Q3 2024 per OTLK's latest filing, from $404593.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $404593.0 in Q2 2024 and troughed at $239951.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -14.79 Mn |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 239,951.00 |
| Jun 30, 2024 | 404,593.00 |
| Sep 30, 2023 | 306,021.00 |
| Jun 30, 2023 | 395,537.00 |